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Hematopoietic stem cells (HSCs) are responsible for the generation of the body’s whole 
blood and immune cells. This process occurs mainly within the bone marrow 
microenvironment, known as the "niche", which provides signals to regulate HSC 
survival, quiescence, self-renewal, and differentiation. This niche microenvironment is 
comprised of cellular components, extracellular matrix (ECM), and soluble cytokines and 
growth factors. Although the understanding of these signals is growing, there is still no 
well-established in vitro system to study the role of these signals in hematopoiesis; such 
knowledge could be utilized to expand HSCs for clinical use. In addition, a growing 
number of studies have shown that alteration of the bone marrow niche is associated 
with leukemia resistance and progression. Here we used decellularized Wharton's jelly 
matrix (DWJM), the ECM part of umbilical cord, as a scaffold to engineer a 
hematopoietic niche for normal and malignant hematopoiesis. The findings that DWJM 
prevents the loss of hematopoietic stem cell characteristics and that it enriches a 
leukemia stem cell (LSC) – like population indicate that this natural ECM biomaterial is a 
suitable in vitro model of the bone marrow microenvironment that could be utilized to 
expand HSPCs (hematopoietic stem and progenitor cells) and to provide a potential 
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Hematopoiesis and hematopoietic stem cells (HSCs) 
Hematopoiesis is a process in which the pluripotent HSCs continuously and dynamically 
give rise to various types of blood cells. During development, primitive hematopoiesis 
occurs in the yolk sac, and followed by definitive hematopoiesis in the 
aorta-gonad-mesonephros (AGM) region, then in the fetal liver, spleen, and finally in 
bone marrow (Wang and Wagers 2011). Except for some specialized lymphocytes, 
mature blood cells are short-lived and thus need to be replenished throughout life to 
maintain homeostasis. HSCs, which are the cells at the top of the hematopoietic 
hierarchy, are responsible for hematopoietic homeostasis. After each cell division, one 
HSC can generate at least one daughter cell exactly the same as the parent, known as 
self-renewal, and another cell which can subsequently differentiate into all the 
hematopoietic lineages, referred to as multipotency (Bylinkina, Golubeva et al. 1991, 
Weissman, Anderson et al. 2001). In the bone marrow, the highly dormant and long-term 
repopulating HSCs (LT-HSCs) are a reserve pool of the most potent HSCs, and are 
activated only during stress or injury; once active, the self-renewing short-term HSCs 
(ST-HSCs) are mainly responsible for hematopoietic homeostasis (Ehninger and 
Trumpp 2011). Cell differentiation occurs from the stem cells to multipotent progenitors 
(MPPs), and then to myeloid or lymphoid progenitors, which have restricted 
developmental potentials, and subsequently generate all the myeloid (erythrocytes, 
platelets, granulocytes, macrophages) and lymphoid cells (T cells, B cells, nature killer 
cells). HSCs can also migrate to the circulation and home back to bone marrow 
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especially via signaling molecules like granulocyte colony-stimulating factor (G-CSF), or 
in response to chemotherapy, or under stress. The circulating HSCs also contribute to 
hematopoiesis, mainly by entering the peripheral hematopoietic organs like spleen and 
liver, and by triggering increased hematopoietic cell proliferation and differentiation 
under stress (Trumpp, Essers et al. 2010).  
One barrier for studying HSCs is the identification of this rare population (Kiel, Yilmaz et 
al. 2005). Perhaps the best way to identify HSCs is to use serial transplantation to test 
stemness (Lemischka, Raulet et al. 1986). NSG (NOD scid gamma) mice is currently the 
most widely used immunocompromised model and serve as a useful tool for in vivo 
analysis of human HSCs(Shultz, Ishikawa et al. 2007). However, there is no ideal in vitro 
assay to specifically identify these cells. Colony-forming assay detects cells that give rise 
to large colonies but they can also be short-term progenitors. Long-term culture initiating 
cell (LTC-IC) assays can detect some but not all HSCs, which are more primitive than 
colony forming cells.  
Since overwhelming studies of hematopoiesis are based on mouse models, the isolation 
and identification of mouse HSCs are more well-established. HSCs and MPPs do not 
express the surface markers that are associated with the terminal differentiation of 
specific blood cell types. Lack of expression of these lineage (lin) markers including CD3 
(T cell), B220 (B cell), Gr1 (granulocyte), Mac1 (monocyte), and Ter119 (erythrocyte) 
which includes all of the mature hematopoietic cells can be used to isolate mouse 
hematopoietic stem and progenitor cells (HSPCs) from the more differentiated cells. 
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Further, murine bone marrow HSCs do not express cell-surface markers of 
lineage-committed hematopoietic cells (Lin-) but do express high levels of Sca-1 and 
c-Kit, referred to as the LSK (Lin–Sca-1+c-Kit+) cells. Additional markers like CD150, 
CD244, and CD48 increased the specificity (Kiel, Yilmaz et al. 2005). Other studies have 
indicated that LSK in combination with Flk2 and CD34 can be used to identify long-term 
reconstituting HSCs (LT-HSCs, CD34-FLT3–) (Osawa, Hanada et al. 1996), short-term 
HSCs (ST-HSCs, CD34+FLT3–) and multipotent progenitors (MPP, CD34+FLT3+) 
(Purton and Scadden 2007). 
Like in mouse, primitive human hematopoietic cells do not express lineage specific 
markers (i.e., CD3, CD4, CD8, CD14, CD15, CD16, CD19, CD20, CD56, and CD66b). In 
human, CD34 is the most widely accepted marker for the primitive hematopoietic cells to 
enrich HSPCs for both research and clinical use. The frequency of CD34+ cells is 1-4% 
of the nucleated cells in normal human bone marrow (BM) aspirate and <0.1% of 
nucleated cells in human peripheral blood under homeostasis (Eaves, Glimm et al. 2001). 
However, many of CD34+ cells are lineage-restricted progenitors while HSCs is still a 
small proportion within CD34+ cells. Efforts to purify HSCs have been done based on 
efflux of vital dyes like Hoechst, functional markers such as the detoxifying enzyme 
aldehyde dehydrogenase (ALDH) (Frandberg, Borestrom et al. 2015). Other studies 
have shown that HSCs can be enriched further on the basis of CD45RA, Thy1,and CD38 
expression (Baum, Weissman et al. 1992, Craig, Kay et al. 1993, Mayani, Dragowska et 
al. 1993, Hao, Shah et al. 1995, Bhatia, Wang et al. 1997, Majeti, Park et al. 2007). Then 
CD49f was used to distinguish HSCs from MPP, and this is so far the most convincing 
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combination of cell surface markers to label LT-HSCs, ST-HSCs and MPPs tested based 
on transplantation in mouse model (Notta, Doulatov et al. 2011). 
Since HSCs are responsible for producing the whole hematopoietic system, mutations 
occurring during hematopoiesis can lead to many diseases like leukemia, myeloma, 
lymphoma, and anemia. Since many of those diseases are fatal even with drug 
treatment, HSC transplantation (HSCT) is widely used to treat patients with 
life-threatening hematologic diseases. HSCT involves the elimination of a patient’s blood 
and immune system by chemotherapy or radiotherapy, and replacing it with 
hematopoietic stem and progenitor cells (HSPC) either from another donor or the 
patient’s own previously collected stem cells. Traditionally, stem cells are collected from 
bone marrow and peripheral blood. To collect stem cell from bone marrow, the clinical 
practitioners give the donor a general anesthetic and 500-1200ml bone marrow aspirate 
is harvested from the pelvis. The mononuclear cells are counted to estimate the yield. 
This collection process is invasive, and donors undergo severe pain without anesthesia. 
Peripheral blood stem cells are collected by a cell separator instrument connected to the 
donor via peripheral cannula. The donor’s blood goes through the cannula and pumped 
into the cell separator instrument. The mononuclear cells are collected by the machine 
and the red blood cells go back to the donor’s blood circulation. This process, called 
apheresis, takes a few hours to get enough cells for transplantation. Because during 
homeostasis, the number of hematopoietic stem cells in the blood circulation is 
extremely low, chemotherapy (only in autologous transplantation) and growth factors 
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(usually G-CSF) are administrated into the donors to increase the stem cells before 
collection of peripheral stem cells. This collection method is dependent on the stem cell 
mobilization, so sometimes it requires repeated collections. A cell dose of 2-4x108 
nucleated cells /kg recipient body weight is needed, if the stem cell source is bone 
marrow, or 2.5x106 CD34+ cells/kg body weight, if the source is peripheral blood, for 
successful transplantation. Cord blood is another source of stem cells used in 
transplantation, especially in pediatric patients, since fetal blood contains a large number 
of hematopoietic stem cells. An estimated 20,000 umbilical cord blood transplants have 
been performed worldwide to treat patients with malignant and nonmalignant diseases 
(Aljitawi 2012, Lund, Boitano et al. 2015). Compared with bone marrow and peripheral 
blood, cord blood not only contains higher frequency of HSPCs, but is also associated 
with lower rate of graft-versus-host disease (GVHD) post-transplantation. The source of 
cord blood normally is limited and the amount is small with each transplantable unit often 
ranging in volume from 60 to 100ml. On the other hand, the hematopoietic reconstitution 
ability of the stem cells in cord blood is higher than other stem cell sources, thus a lower 
cell dose of CD34+ cells/kg body weight is needed compared with peripheral blood 
(Ballen, Gluckman et al. 2013).  
Hematopoietic stem cell niche 
Under normal conditions, HSCs reside in a specialized bone marrow microenvironment, 
also known as the stem cell niche. The bone marrow is a soft structure within the highly 
vascularized trabecular bone and is the main site for hematopoiesis (Gurkan and Akkus 
7 
 
2008). Since the term “stem cell niche” was first proposed by Schofield more than 30 
years ago (Schofield 1978), many studies have been focused on illustrating the 
components and their role in HSC self-renewal and differentiation. Niche components 
regulate the fate of HSCs by direct cell–cell contact, or by producing a range of growth 
factors, cytokines, chemokine, and extracellular matrix (ECM) (Lymperi, Ferraro et al. 
2010). The stem cell niche is a highly dynamic microenvironment which does not only 
influence the HSCs and the hematopoietic cells derived from HSCs, but could also be 
remodeled by them. 
1. Cellular components of HSC niche 
Endothelial cells. So far, multiple niche components have been elucidated for HSCs. 
Recent studies based on advanced bone marrow imaging technologies and genetic 
ablation mouse models have indicated that the HSCs are mostly perivascular (Xie, Yin et 
al. 2009, Kunisaki, Bruns et al. 2013, Nombela-Arrieta, Pivarnik et al. 2013, Acar, 
Kocherlakota et al. 2015). In the perivascular niche, cells of the vasculature are of great 
interest. Actually, it has been shown that the endothelial cells and hematopoietic cells 
are from the same precursor—the hemangioblast (Shalaby, Rossant et al. 1995, 
Kennedy, Firpo et al. 1997). These cells are usually identified by their expression of the 
endothelial-specific markers CD31, MECA-32, V-cadherin and vascular endothelial 
growth factor receptor 2 (VEGFR2), and line the surface of blood vessels, connecting the 
blood and tissues in the bone marrow. Imaging analyses reveal that HSPCs can be 
found co-localized with the marrow vasculature both in the central bone and endosteal 
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regions (Xie, Yin et al. 2009, Kunisaki, Bruns et al. 2013, Nombela-Arrieta, Pivarnik et al. 
2013). This supports the concept that endosteal and vascular niches are not absolutely 
independent from each other but exists in an overlapping manner; since there is a dense 
vascularization within the bone marrow. In vivo studies suggest that vascular endothelial 
cells are critical for maintenance of HSPCs within bone marrow as well as their function 
of hematopoietic system reconstitution after bone marrow injury (Li, Bailey et al. 2010, 
Ding, Saunders et al. 2012). Endothelial cells regulate the HSC retention in bone marrow, 
self-renewal and differentiation by expressing many factors in both contact dependent 
and independent ways. These factors include, but not limited to, secreted proteins like 
stem cell factor (SCF) and  stromal cell-derived factor 1 (SDF1) (Kennedy, Firpo et al. 
1997, Ding, Saunders et al. 2012, Ding and Morrison 2013, Greenbaum, Hsu et al. 2013), 
Notch ligands(Butler, Nolan et al. 2010), angiopoietin 1 (ANGPT1)(Arai, Hirao et al. 
2004), pleiotrophin (Himburg, Harris et al. 2012), and epidermal growth factor (EGF) 
(Doan, Himburg et al. 2013), and membrane-bound proteins such as E-selectin, which 
promotes HSC proliferation and increases HSC chemo-sensitivity (Winkler, Barbier et al. 
2012). Bone marrow-derived endothelial cells have shown some capacity to facilitate 
HSC ex vivo expansion (Rafii, Shapiro et al. 1995, Butler, Nolan et al. 2010), while 
endothelial cells from other sources showed varying degrees of expansion support 
(Avecilla, Hattori et al. 2004, Qu, Liu et al. 2016). Limited in vivo data suggests the 
vascular niche may be particularly important in the activation of HSCs for hematopoiesis, 
as shown by enhanced proliferating HSCs recruitment to the perivascular region 




Perivascular MSCs. Among all of the cells in the bone marrow microenvironment, 
mesenchymal stem cells have long been studied for their roles in HSC fate decision. As 
a rare cell population within the bone marrow (1 in 10,000 nucleated cells) (Friedenstein, 
Chailakhjan et al. 1970), they are able to give rise to the entire mesenchymal lineages 
including bone, cartilage and fat cells, as well as various fibroblast-like stromal cells 
producing HSC supporting factors and serving as scaffolds alone or by producing ECM 
components in the bone marrow (Pittenger, Mackay et al. 1999, Liechty, MacKenzie et al. 
2000, Lin, Moreno-Luna et al. 2014). The unique properties of this cell population make 
them popular in the research of regenerative medicine and tissue engineering. Previous 
studies have focused on elucidating the specific cell surface marker for the proper 
isolation and identification of MSCs but the conclusions are still inconsistent. Diverse 
antigens have been found on the surface of MSC, but none of them is unique to the cells 
(Rostovskaya and Anastassiadis 2012, Lv, Tuan et al. 2014). According to the 
International Society for Cellular Therapy (ISCT), the minimal criteria for MSCs are: (1) 
adhesion to plastic culture dish under the standard culture conditions; (2) expression of 
CD105, CD73 and CD90, but not lineage markers such as CD45, CD34, CD14 or CD11b, 
CD79alpha or CD19 and HLA-DR; (3) the ability to differentiate into osteoblasts, 
adipocytes and chondrocytes in vitro (Dominici, Le Blanc et al. 2006). Some recent 
studies based on transgenic mouse models found that the bone marrow MSCs located 
adjacent to vasculature are important for the HSC maintenance and cell fate decision 
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((Mendez-Ferrer, Michurina et al. 2010; Ding, Saunders et al. 2012; Kunisaki, Bruns et al. 
2013). Different markers have been used to identify these cells including nestin 
(Nes)-GFP (Mendez-Ferrer, Michurina et al. 2010), leptin receptor (LEP-R) (Ding, 
Saunders et al. 2012), neuron/glial antigen 2 (NG2) (Kunisaki, Bruns et al. 2013), Paired 
related homebox 1 (Prx-1) (Greenbaum, Hsu et al. 2013), platelet-derived growth factor 
receptor alpha (PDGFRA or CD140a), CD51 and Sca-1 (Pinho, Lacombe et al. 2013), 
CD146 (Sacchetti, Funari et al. 2007) and CD271 (Matsuoka, Nakatsuka et al. 2015). 
Although the markers used in these studies are different from each other, they have all 
been shown to support HSC self-renewal and multipotency. However, the distribution of 
HSCs and the MSC population having direct contact with them remain controversial. 
While NG2+LEP-R− peri-arteriolar MSCs close to endosteal area were first reported to 
be associated with quiescent HSCs, and NG2−LEP-R+ peri-sinusoidal MSCs which are 
peri-sinusoidal and located in central bone away from the endosteum are associated 
with activated HSCs (Kunisaki, Bruns et al. 2013), a recent study indicated that both the 
quiescent and active HSCs prefer to localize in the peri-sinusoidal area with LEP-R+ 
MSCs (Acar, Kocherlakota et al. 2015). However, these findings from both these groups 
illustrate the importance of CXCL12 and SCF expressed by the MSCs. Actually, the 
perivascular stromal cells expressing high amounts of CXCL12, known as 
CXCL12-abundant reticular (CAR) cells, maintain the quiescent HSC pool by regulating 
their self-renewal, proliferation and trafficking (Sugiyama, Kohara et al. 2006). It seems 
that these cells are more differentiated progenitors with adipogenic and osteogenic 
potential (Omatsu, Sugiyama et al. 2010). So far, it is widely recognized that these 
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perivascular MSCs play an important role in the maintenance of HSCs within the bone 
marrow niche shown by many in vivo studies based on genetically engineered mice. 
These studies either ablated the whole MSC population expressing CXCL12 (Omatsu, 
Sugiyama et al. 2010), or specifically knocked out CXCL12 or SCF in Lep-R+ MSCs 
(Ding, Saunders et al. 2012, Ding and Morrison 2013). 
Megakaryocytes. Megakaryocytes are terminally differentiated hematopoietic cells 
responsible for the production of platelets. The concept that megakaryocyte population is an 
essential part of HSC niche was just established in recent years (Bruns, Lucas et al. 2014, 
Nakamura-Ishizu, Takubo et al. 2014, Zhao, Perry et al. 2014). Previous studies found 
that after transplantation HSCs lodge near megakaryocytes (Heazlewood, Neaves et al. 
2013), and the indirect influence of megakaryocytes on HSCs is due to its promotion of 
osteoblastic niche expansion (Olson, Caselli et al. 2013). Then recent studies discovered 
that megakaryocytes also directly regulate HSCs as they promote HSC quiescence by 
secreting CXCL4 (Bruns, Lucas et al. 2014), TGF-β1 (Zhao, Perry et al. 2014) and TPO 
(Nakamura-Ishizu, Takubo et al. 2014) during homeostasis, and activate HSCs by 
producing FGF1 under regenerative stress (Zhao, Perry et al. 2014). However, whether 
the activation is at the expense of losing self-renewal ability is still not clear. The location 
of these megakaryocytes is peri-sinusoidal, indicating that these cells are part of the 
sinusoid niche independent of arterioles. Since a recent study also found that most 
quiescent HSCs reside in peri-sinusoidal niche, whether the endothelial cells, pericytes 
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and megakaryocytes cooperate or each has a distinct role in regulating HSC quiescence 
is worth studying in the future.  
Osteoblasts. The role of the bone-forming osteoblasts is controversial. The endosteal 
niche was originally proposed since the first in vivo studies demonstrated that 
osteolineage cells, the interface between the bone and the bone marrow had direct 
contact with HSCs and were required for HSC maintenance by BMP signaling and Notch 
signaling (Calvi, Adams et al. 2003, Zhang, Niu et al. 2003). Differentiating osteoblasts 
express many factors important for HSC function including CXCL12, SCF and ANGPT1 
(Blair, Dong et al. 1999, Shahnazari, Chu et al. 2013, Zhou, Ding et al. 2015). They also 
produce extracellular matrix proteins including collagen, fibronectin, laminin, vitronectin, 
osteopontin and osteonectin (El-Amin, Lu et al. 2003). However, some later studies have 
shown that some osteolineage cells are partially dispensable in adult BM without 
compromising the long-term HSC maintenance under homeostasis (Ding, Saunders et al. 
2012, Ding and Morrison 2013, Frenette, Pinho et al. 2013, Greenbaum, Hsu et al. 2013). 
According to these studies, deletion of Scf or Cxcl12 expression in osteoblasts does not 
affect HSC number and hematopoietic reconstitution ability but rather reduces the 
numbers of B lymphoid progenitors (Ding and Morrison 2013, Greenbaum, Hsu et al. 
2013). In vitro B cells differentiation requires attachment to osteoblasts through the 
effects of VCAM-1, SDF-1, and IL-7 signaling induced by parathyroid hormone (PTH) 
(Rankin, Wu et al. 2012). Osteoblasts also produce EPO to modulate erythropoiesis 
through HIF signaling (Rankin, Wu et al. 2012). All together it seems that these 
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bone-forming cells play a more important role in the lineage commitment than the 
maintenance of HSCs.  
Other cellular components in bone marrow niche. Some other cell types have also been 
shown to regulate HSC quiescence and activation, self-renewal and lineage commitment. 
These include macrophages, sympathetic nerve system, and adipocytes (Katayama, 
Battista et al. 2006, Naveiras, Nardi et al. 2009, Mendez-Ferrer, Michurina et al. 2010, 
Winkler, Sims et al. 2010, Chow, Lucas et al. 2011). Macrophages regulate HSC 
trafficking and differentiation by interacting with MSCs and osteoblasts to regulate their 
expression of SCF, CXCL12, and IL7 (Winkler, Sims et al. 2010, Chow, Lucas et al. 
2011). The noradrenergic nerves functions to regulate HSC trafficking by interacting with 
nestin+MSCs through their β3-adrenergic receptor, resulting in the down regulation of 
HSC maintenance genes SCF, CXCL12, Angpt1 and vascular cell adhesion molecule 1 
(Vcam-1), making HSCs egress from the bone marrow (Katayama, Battista et al. 2006, 
Mendez-Ferrer, Michurina et al. 2010). Nonmyelinating Schwann cells wrapping around 
sympathetic nerves, help keep HSCs quiescent by expressing TGF-β1 (Yamazaki, Ema 
et al. 2011). Adipocytes are considered as a negative regulator in the bone marrow niche 
since HSC engraftment is accelerated after bone marrow adipocyte ablation (Naveiras, 
Nardi et al. 2009). 
2. Extracellular matrix.  
In the BM, a complex network of extracellular matrix (ECM) including but not limited to 
fibronectins, laminins, collagens, and proteoglycans support hematopoiesis. By imaging 
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the main ECM proteins in mouse bone marrow, researchers have found that these 
proteins have different distributions in the bone marrow, suggesting that they play 
different roles in HSC homing and lodgment after transplantation (Nilsson, Debatis et al. 
1998). The ECM affect the HSCs in both direct and indirect ways, since it can bind to cell 
surface receptors directly, or serve as a reservoir for soluble growth factor that can be 
presented to HSCs. Integrins, the heterodimeric transmembrane molecules consisting of 
an α and β subunits (Hynes 1992), are the most widely studied cell-surface receptors 
binding to ECM thus inducing homing, adhesion, survival, proliferation and differentiation 
of HSCs in the niche (Legate, Wickstrom et al. 2009). For example, tenascin-C produced 
by stromal cells and endothelial cells, is up-regulated during hematopoietic recovery 
after myeloablation. Although knocking out tenascin showed normal steady-state 
hematopoiesis in mice, it could be fatal after bone marrow ablation; in vitro culture of 
HSCs on tenascin-C promoted their proliferation via its receptor integrin α9, suggesting 
this ECM protein is a critical component of the bone marrow microenvironment required 
for hematopoietic reconstitution (Nakamura-Ishizu, Okuno et al. 2012). Integrin α6, the 
receptor of laminin, collaborates with integrin α4 to facilitate the homing of HSCs after 
transplantation (Qian, Tryggvason et al. 2006). Deletion of integrin α4 results in the 
HSCs leaving bone marrow to the blood circulation and accumulation in the spleen under 
homeostasis, delayed erythroid and myeloid progenitor regeneration under stress, and 
impaired homing and engraftment after transplantation (Scott, Priestley et al. 2003). 
Mouse HSCs cultured in fibronectin and laminin expanded CFU-GEMM while increasing 
the cell surface proteins CD29, VLA-4, and MDR, which are all the characteristics of 
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primitive HSCs (Sagar, Rentala et al. 2006). A few non-integrin receptors also have been 
found to be important in HSC trafficking and lodgement. For example, CD44, the 
receptor of glycosaminoglycan hyaluronan, cooperate with SDF-1 to mediate HSC 
homing after transplantation (Sagar, Rentala et al. 2006).  
Engineering HSC niche in vitro 
The clinical use of HSCs in transplantation to treat patients suffering from hematological 
disorders relies on their potential to reconstitute all the hematopoietic system. However 
this usage, especially for cord blood HSC transplantation is hampered by the limited 
availability because of the low cell number collected each time regardless of the source. 
Currently the most elegant solution for overcoming the problem is to expand these cells 
ex vivo prior to infusion. The manipulation of these cells in vitro will not only allow the 
enhanced availability of a larger cell population for HSCs, but also can potentially 
increase their homing ability if using appropriate methods to induce the “homing factors” 
such as CXCR4 and C3a receptor (Lund, Boitano et al. 2015), to improve clinical 
outcomes. In vitro mimicking the niche where hematopoiesis occurs would help 
understand the interactions between HSCs and their microenvironment including the 
niche cell, and biophysical / bimolecular signals, thus leading to successful expansion of 
HSCs while maintaining their stem cell properties. To date, a variety of culture systems 
have been established to elucidate the microenvironmental cues on HSC fate decisions. 
The design of these systems mainly include biomaterial-based culture platforms, 
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co-culture with different niche cells, and a three dimensional (3D) biomaterial-based 
co-culture system. 
Two dimensional (2D) culture systems. In vitro culture of hematopoietic cells can be 
stroma-free or stroma-dependent. Stroma-free cultures are the most conventional cell 
suspension in medium supplemented with cytokine cocktails. It is easy to perform and 
control specific factors influencing HSC fate decision. However, given that more and 
more evidence has shown niche cells have significant effects on the survival, 
proliferation, quiescence, self-renewal and differentiation of HSCs, co-culture of HSCs 
with these feeder cells is a common strategy to study the cell-cell interaction in bone 
marrow niche. Bone marrow stromal cells are the most commonly used cell population 
for ex vivo expansion of HSCs (Verfaillie 2002, Sauvageau, Iscove et al. 2004). Here, 
culture with bone marrow MSCs (Jing, Fonseca et al. 2010), endothelial cells (Chute, 
Saini et al. 2002), and osteoblasts (Chute, Saini et al. 2002) have all been shown to 
expand HSCs while maintain their long-term reconstitution ability. Feeder cells can also 
induce the differentiation of HSPCs into committed lineages including erythroids, 
megakaryocytes, NK cells, T cells, and B cells (Vieira and Cumano 2004, Giarratana, 
Kobari et al. 2005, Taqvi, Dixit et al. 2006, Dezell, Ahn et al. 2012). The feeder layers 
functions both by direct cell-cell contact via adhesion molecules, or by secreting 
cytokines and growth factors, acting in a paracrine manner.  
Scaffold-based three dimensional (3D) cell cultures. The natural bone marrow niche is a 
3D soft marrow where HSCs reside in the highly viscous and porous spongiosa 
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environment. This 3D environment consists of structural elements and signals that affect 
the cells from all aspects, including the local accumulation and depletion of diffusible 
growth factors. Such effects cannot be recapitulated by the conventional 2D culture 
systems. Highly porous scaffolds have been used as culture platforms for HSCs. The 3D 
porous materials provide more space than the 2D conditions thus facilitate higher cell 
densities (Li, Ma et al. 2001). In addition, such scaffolds help construct the biophysical 
and mechanical function of the bone marrow microenvironment. Mouse ESCs tended to 
differentiate into HSCs in PLLA scaffolds with smaller pore sizes and higher polymer 
concentrations, indicating that pore size and viscosity are important in HSC fate decision 
(Taqvi and Roy 2006). Another study compared several commonly used scaffolds (PCL, 
PLGA, fibrin, collagen) to culture cord blood HSCs, showing that fibrin pre-seeded with 
MSCs support HSC expansion mostly, while 3D PLGA scaffolds led to poor HSC survival 
and did not induce adhesion of HSCs, suggesting that not only the pore size, but the 
composition of scaffolds is also important; scaffolds with natural BM ECM components 
support HSC growth better than synthetic ones (Taqvi and Roy 2006). Culture wells 
coated with collagen preseeded with MSCs promoted HSPC proliferation while forming 
cobblestone-like clusters, as well as the formation of a sinusoid-like structure indicate 
that by using an ideal ECM mimicking material, it is highly possible to recapitulate the 
bone marrow niche in vitro (Leisten, Kramann et al. 2012). 
Although the scaffold-based 3D culture systems facilitate the distribution of stromal and 
hematopoietic cells thus increase cell-matrix interactions and mimic the stem cell niche 
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for expansion of the desired cell type for potential clinical use, there are still some 
unknowns in terms of the design and fabrication of such 3D scaffolds. Although there is 
growing knowledge on HSCs in cell and molecular biology perspective, the impact of 
bone marrow microenvironment biophysical properties on HSC fate decision still 
requires exploration. The design, reproducibility and standardization of the scaffold 
structure, and the subsequent standardized culture protocols are areas need to be 
addressed and optimized for clinical usage.  
The bone marrow niche in acute myeloid leukemia (AML) 
In the bone marrow, the hematopoietic stem and progenitor cells are exposed to various 
stresses which would cause mutations, and the accumulation of the mutations can then 
give rise to leukemia stem cells (LSCs). The mutations can occur both in the highly 
self-renewal HSCs stage and more committed myeloid progenitors, since LSCs have 
been found with phenotypes of both (Goardon, Marchi et al. 2011). These characteristics 
of LSCs make it difficult to find out specific markers to isolate them. So far one of the 
best ways to characterize LSCs is to test their ability to initiate this disease in serial 
transplantations based on animal models. Since people believe that LSCs reside within 
bone marrow and can cause relapse even after the chemotherapeutic ablation of all the 
leukemia cells in the circulation, as well as the fact that it is difficult to culture patient 
leukemia samples in vitro, it is highly possible that LSCs depend on the bone marrow 
niche for their survival and propagation like HSCs. In addition, as the propagation of 
malignant hematopoietic cells is at the expense of normal hematopoiesis, LSCs may 
19 
 
exploit the HSC niche, and further modulate the niche components on which normal cells 
depend (Schepers, Campbell et al. 2015). Examining the interaction between leukemia 
and hematopoietic niche may provide opportunities for treatment design. 
Like solid tumors, highly proliferating AML cells require increased angiogenesis in many 
patients (Hussong, Rodgers et al. 2000, Padro, Ruiz et al. 2000). The expansion of 
vasculature in the bone marrow of AML patients is usually associated with poor 
prognosis (Rabitsch, Sperr et al. 2004). Studies have found that AML cells localize to 
endosteal niche (Hatfield, Oyan et al. 2009), inducing proliferation of microvascular 
endothelial cells through secreting CXCL8 (Cogle, Goldman et al. 2014). On the other 
hand, in the vascular niche a subset of AML cells adhere to endothelial cells through 
the cell adhesion molecule E-selectin or even fuse with endothelial cells to enter a 
quiescence state which give rise to chemoresistance (Pezeshkian, Donnelly et al. 2013, 
Cogle, Goldman et al. 2014). Interestingly these leukemia-derived endothelial cells are 
able to initiate leukemia after transplantation suggesting that these cells maintain a LSC 
function (Cogle, Goldman et al. 2014). In addition, treating endothelial cells with vascular 
disrupting agents could increase AML cell apoptosis through the production of reactive 
oxygen species, indicating that targeting endothelial cells might be a good strategy for 
treating AML (Madlambayan, Meacham et al. 2010). 
Similarly, there is also remodeling of endosteal niche in leukemic bone marrow. In 
mouse models, LSCs have been shown to localize next to osteoblasts (Ninomiya, Abe et 
al. 2007), and osteoblasts protect AML cells from SDF1a-induced apoptosis (Kremer, 
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Dudakovic et al. 2014). Also it appears that malignant myeloid cells can stimulate 
mesenchymal stromal cells (MSCs) to produce osteoblasts through up-regulation of 
RUNX2 and this induces chemo-resistance (Schepers, Pietras et al. 2013). The 
activation of MSC to osteoblastic cell-specific differentiation by parathyroid hormone 
(PTH) receptor enhances AML after transplantation into mouse models via increased 
TGF-β1 signaling on the LSCs (Krause, Fulzele et al. 2013). 
The functions of bone marrow stromal cells (MSCs) on AML have been partially 
elucidated so far. MSCs can provide protective signals supporting survival and 
chemoresistance of AML cells in animal models through SDF-1/CXCR4 axis, 
VCAM-1/VLA-4 interaction, and induction of quiescence (Matsunaga, Takemoto et al. 
2003, Zeng, Shi et al. 2009, Jacamo, Chen et al. 2014).  Studies have also indicated 
that AML cells produce IL10 and G-CSF to enhance the production of growth 
arrest-specific gene 6 (Gas6) by MSCs, thus promotes AML cell survival and 
chemoresistance. In fact, clinical data have reported that GAS6 expression identified 
high-risk adult AML patients by shorter disease-free  and overall survival rate, probably 
by overexpression of BAALC and MN1, SDF-1 and its receptor CXCR4/CXCR7 
(Whitman, Kohlschmidt et al. 2014). AML cells could also disrupt normal hematopoiesis 
while increasing BM infiltration of AML cells by inducing loss of HSC supporting 
peri-arteriolar NG2+ MSCs and nerve fibers, resulting in the down-regulation of SDF-1 
and SCF which are necessary for the maintenance of HSCs in bone marrow (Hanoun, 
Zhang et al. 2014).   
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Altogether, these studies demonstrate that AML cells would not only recognize and 
hijack the bone marrow niche for normal HSCs, but can also transform the niche to a 
leukemia-favorable microenvironment to support the survival of malignant cells. Since 
patient leukemia cells are difficult to maintain viability in vitro, a cell culture model 
mimicking the bone marrow niche to support the long-term culture of patient samples is 

































HSCs reside in the “BM hematopoietic niche”, a special three-dimensional (3D) 
microenvironment that regulates the HSCs self-renewal and multi-potency. In this study, 
we established a 3D culture system that recapitulates the BM hematopoietic niche to 
expand hematopoietic stem and progenitor cells (HSPCs). We used decellularized 
Wharton’s jelly matrix (DWJM) as extracellular matrix (ECM) scaffold and human bone 
marrow (BM) mesenchymal stromal cells (MSCs) as supporting niche cells. . We 
assessed the efficacy of the DWJM-based 3D culture condition with or without BM MSCs 
by analyzing  proliferation, apoptosis, self-renewal, lineage differentiation, and homing 
potential of umbilical cord CD34+ (UCBCD34+) HSPCs. Our results indicate that DWJM 
alone promotes HSPC quiescence while maintaining their viability and clonogenic 
capacity. DWJM culture also increases frequency of c-kit+ HSPCs, a population with 
enhanced self-renewal ability. Furthermore, DWJM alone induces expression of CXCR4, 
thereby enhancing HSPC migration toward stromal cell-derived factor-1 (SDF-1) .  
In contrast, DWJM with BM MSCs highly stimulates proliferation of HSPCs and 
decreases their transmigration potential towards SDF-1 by suppressing CXCR4 
expression. In conclusion, the DWJM and BM MSC culture condition provides a model 
system to study importance of distinct components of BM hematopoietic niche on HSPC 
quiescence, proliferation and differentiation and could potentially serve as a HSPC 





Hematopoiesis is the process of generating blood and immune cells in the body from a 
very small number of hematopoietic stem cells (HSCs). HSCs reside in the “BM 
hematopoietic niche”, a special microenvironment that regulates the HSCs self-renewal 
and multi-potency. Since the “niche” concept was first proposed by Schofield in 1978 
(Schofield 1978), many studies have focused on understanding the niche-HSC 
interactions by using both in vivo mouse models and in vitro culture systems (Butler, 
Nolan et al. 2010, Ding, Saunders et al. 2012, Ding and Morrison 2013, Li, Ghazanfari et 
al. 2014, Acar, Kocherlakota et al. 2015, Zhou, Ding et al. 2015, O'Hagan-Wong, 
Nadeau et al. 2016). The main components of bone marrow (BM) hematopoietic niche 
are the HSC surrounding cells including MSCs, osteoblasts and endothelial cells. In 
addition, multiple ECM proteins (collagen, fibronectin, tenacin) along with cytokines and 
growth factors, which bind or diffuse into ECM are important components of the BM 
niche (Schepers, Campbell et al. 2015). 
The BM components control the size of the HSC pool and regulate the HSC fate 
during normal homeostasis and under stress. For example, MSCs, which are the 
precursor cells of all mesenchymal cell types in the hematopoietic niche like adipocytes, 
osteoblasts and fibroblasts, play a critical role in HSC self-renewal and mobilization 
(Ding, Saunders et al. 2012, Ding and Morrison 2013, Acar, Kocherlakota et al. 2015, 
Zhou, Ding et al. 2015). ECM components also influence the trafficking and lodging of 
HSCs by interacting with their receptors on the cells surface. It has been postulated that 
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the calcium sensing receptor on HSCs could increase CXCR4-SDF-1 signaling and 
promote HSCs adherence to collagen in the ECM (Lam, Cunningham et al. 2011). Also 
hyaluronic acid in ECM could synergize with SDF-1 to enhance the homing ability of 
HSCs into BM (Avigdor, Goichberg et al. 2004). However, the precise mechanisms by 
which the BM niche components regulate HSC quiescence vs. proliferation vs. 
differentiation is still poorly understood.  
The nature of HSCs makes them widely used in stem cell transplantation to treat 
malignant and non-malignant hematopoietic diseases as well as metabolic disorders.  
The main sources of HSCs are BM, peripheral blood, and cord blood. Compared to 
peripheral blood and BM, cord blood HSCs are non-invasively collected, have a greater 
proliferation potential, require less HLA matching, and when transplanted are associated 
with decreased rates of transmissible infections and graft-versus-host disease (GVHD) 
(Aljitawi 2012). However, cord blood HSC transplantation is usually associated with 
higher rates of graft failure, delayed engraftment, and poor immune reconstitution 
(Aljitawi 2012), mainly because of the lower cell dose, and probably the relatively high 
proportion of more primitive CD34+CD38- stem cells but much lower proportion of 
committed progenitors (Gomi, Hasegawa et al. 1997, Wang, Doedens et al. 1997), which 
contribute to short-term hematopoietic reconstitution. Currently the impact of different 
components of BM niche on niche-HSC interactions are mostly studied in vivo mouse 
models, mainly through knocking out some specific molecules produced by a subset of 
niche cell population (Ding, Saunders et al. 2012, Ding and Morrison 2013, Zhou, Ding et 
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al. 2015). However, these animal models are unable to recapitulate the unique human 
BM microenvironment and its influence on hematopoiesis. Accordingly, it is essential to 
develop new experimental system that could mimic human BM microenvironment.  
Previously many studies have used niche cells to establish co-culture systems to 
study the cell-cell interaction between HSCs and the feeder cells. The co-culture with BM 
stromal cells, osteoblasts, and endothelial cells increased HSC proliferation while 
inducing multi-lineage differentiation with some lineage preference (Fraser, Szilvassy et 
al. 1992, Calvi, Adams et al. 2003, Friel, Heberlein et al. 2005, Jing, Fonseca et al. 2010, 
Yang, Ma et al. 2013, Huang, Li et al. 2016). As the BM is a 3D (three dimensional) 
tissue, 3D culture systems are becoming more popular in engineering hematopoietic 
niches in vitro. However, as biophysical properties including the viscosity and ECM 
composition of BM microenvironment might impact HSC fate decision (Schepers, 
Campbell et al. 2015), an ideal scaffold should have the same mechanical properties of 
the BM microenvironment. There are few types of 3D scaffolds that have been explored 
for HSCs ex vivo culture, including porous matrix, nanofiber meshes, woven and 
non-woven fabrics (Ehring, Biber et al. 2003, Chua, Chai et al. 2007, Mortera-Blanco, 
Mantalaris et al. 2011, Ferreira, Jahnen-Dechent et al. 2012). These scaffolds provide 
biological compatibility for cells to survive, enough space for the cells to adhere, and 
appropriate pore sizes for cells to migrate and exchange nutrients. Some studies have 
used collagen coated substrates to mimic the 3D soft marrow, and it has been shown to 
change the shape, spread, and phenotype of HSCs (Mortera-Blanco, Mantalaris et al. 
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2011, Choi and Harley 2012). However, these models do not recapitulate the BM 
microenvironment as these systems lack the complexity of BM ECM, which is composed 
of many different types of proteins and glycosaminoglycans. Therefore, in this we used a 
novel natural ECM material, DWJM from umbilical cord, as a scaffold to establish a 3D in 
vitro model system to study UCBCD34+ HSPCs fate decision in response to different 
niche components. 
Materials and methods 
1. Enrichment of UCB CD34+ HSPCs 
Fresh UCB units were obtained from St. Louis cord blood bank (St. Louis, MO, USA).  
Mononuclear cells were separated by using Lymphoprep (Stemcell Technologies, 
Canada) density medium followed by immunomagnetic separation of CD34+ cells using 
the EasySep™ Human Cord Blood CD34 Positive Selection Kit (STEMCELL 
Technologies, Canada) according to manufacturer’s protocol. Briefly, blood was diluted 
1:1 in PBS with 2% FBS, and layered on top of density medium in SepMate tubes 
(STEMCELL Technologies, Canada). After centrifugation, mononuclear cells in 
supernatant were centrifuged, washed twice to remove platelets, resuspended in 14ml 
tubes and counted. 1x RBC lysis buffer (STEMCELL Technologies, Canada) was added 
1:1 into the cell suspension, followed by adding nanoparticles recognizing cell surface 
antigen. Tubes were placed in magnet (STEMCELL Technologies, Canada) for 5 
minutes, and then supernatant was poured off. PBS with 2% FBS was added to wash the 
cells and the magnetic step was repeated four times. Enriched cells were centrifuged, 
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counted, and cell purity was measured by flow cytometry. UCB units with more than 90% 
purity were used in our experiments (Fig 1A). CD34+ cells were cultured in StemSpan 
serum-free Medium (Stemcell Technologies, Canada) supplemented with a dilution of 
1:100 cytokine cocktail StemSpan cc110 (Stemcell Technologies, Canada) including 
recombinant human Flt-3 Ligand, Stem Cell Factor, and Thrombopoietin.  
2. Isolation of bone marrow MSCs 
Human bone marrow stromal cells (MSCs) were isolated from bone marrow aspirates 
collected from healthy donors at the University of Kansas Medical Center (HSC # 5929). 
The mononuclear cells from bone marrow aspirates were separated by using 
Lymphoprep (Stemcell Technologies, Canada) density medium according to 
manufacturer’s instructions. Briefly, bone marrow aspirated were diluted 1:1 in PBS, and 
layered on top of density medium in SepMate tubes (STEMCELL Technologies, Canada), 
washed, and centrifuged to form pellets. After isolation, cells were counted, and cultured 
in high glucose Dulbecco’s Modified Eagle’s Medium (DMEM) with 20% FBS and 1% 
pen/strep at 37°C with 5% CO2 overnight in T75 culture flasks. The next day, 
non-adherent cells were removed, and the adherent cells were cultured until use. A MSC 





Figure 1.Characterization of the hematopoietic niche components. (A) Freshly 
enriched umbilical cord blood (UCB) CD34+ HSPCs with more than 90% purity and (B) 
bone marrow stromal cells with mesenchymal stem cell (MSC) phenotype 
CD73+CD105+CD90+CD14-CD20-CD34-CD45- were used to establish the 3D 

























positive for CD73, CD90, CD105, and negative for the hematopoietic cells markers 
CD14, CD20, CD34, and CD45 were used in our study (Fig 1B). The decellularization 
procedure was described in our recent publication (Aljitawi, Xiao et al. 2013). Briefly, the 
surrounding membranes and vascular structures were removed followed by dissecting 
the umbilical cords into large pieces that were subjected to two cycles of osmotic shock 
followed by an anionic detergent (Sodium lauryl) and, sodium succinate (Sigma L5777), 
alternating with a recombinant nucleic acid enzyme (Benzonase™), and followed by 
organic solvent extraction with 40% ethyl alcohol. Next, all of the detergent and other 
processing residuals were removed by ion exchange beads in a reciprocating 
flow-through glass system for 30 hours in ddH2O at room temperature. The 
decellularized matrix was cryopreserved using 10% human recombinant albumin 
(Novozymes) and 10% DMSO (Sigma) solution in RPMI 1640 media, employing a 
material specific computer controlled freezing profile that was developed to freeze at 
-1°C/minute to -180°C. 
3. Decellularization of Wharton’s jelly matrix 
The decellularization procedure was described in our recent publication (Aljitawi, Xiao et 
al. 2013). Briefly, the surrounding membranes and vascular structures were removed 
followed by dissecting the umbilical cords into large pieces that were subjected to two 
cycles of osmotic shock followed by an anionic detergent (Sodium lauryl) and, sodium 
succinate (Sigma L5777), alternating with a recombinant nucleic acid enzyme 
(Benzonase™), and followed by organic solvent extraction with 40% ethyl alcohol. Next, 
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all of the detergent and other processing residuals were removed by ion exchange beads 
in a reciprocating flow-through glass system for 30 hours in ddH2O at room temperature. 
The decellularized matrix was cryopreserved using 10% human recombinant albumin 
(Novozymes) and 10% DMSO (Sigma) solution in RPMI 1640 media, employing a 
material specific computer controlled freezing profile that was developed to freeze at 
-1°C/minute to -180°C. 
4. Preparation of in vitro bone marrow mimetic model 
Enriched CD34+ cells were cultured in cytokine alone as suspension cells, or as an 
adherent cells co-cultured with bone marrow stromal cells forming a monolayer in with 
bone marrow MSCs. Before seeding cells into DWJM, DWJM scaffolds were washed in 
PBS three times, and incubated in culture medium overnight. For co-culture, MSC were 
seeded into culture wells alone as monolayers or into DWJM as 3D systems two days 
before adding CD34+ cells. After enrichment, 3x104 CD34+ cells were seeded (i) in 
suspension without MSCs, (ii) on a monolayer of MSC, (iii) in cell-free DWJM and (iv) in 
DWJM with pre-seeded bone marrow stromal cells (Fig 2A). The three-dimensional 
culture systems are divided into two compartments: CD34+ growing (1) in suspension 
around DWJM and (2) inside DWJM with strong adhesion (Fig 2B). Cells were cultured 
for 7 days at 37°C with 5% CO2. 
5. CellTrace proliferation assay 
Cell division was monitored by using CellTrace proliferation kit (Invitrogen, USA). The 
stable violet fluorescent dye can bind to the amines in the cells covalently, and 
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Figure 2. Preparation of in vitro bone marrow mimetic model. (A) UCB HSPCs were 
cultured in culture wells either: ⅰ) in suspension (control) ⅱ) Over a BM-MSC 
monolayer ⅲ) with DWJM and ⅳ) with DWJM preseeded with BM-MSCs and cultured 
for 7 days in the presence of cytokine supplementation. (B) Histology H&E stained 
sections of the two compartments (Suspension (upper) vs Adherent (bottom)) of 3D 
DWJM-based culture systems. Hematopoietic cells were identified in DWJM (Left) and 
































distributed into two daughter cells equally after each cell division. Soon after enrichment, 
CD34+ cells were labelled with violet dye at a concentration of 1 µl reagent per 106 cells 
suspended in 1 ml PBS, incubated for 20 minutes at room temperature. The reaction 
was stopped by adding PBS with 10% FBS after 5 minutes incubation followed by 
washing with PBS. 
The cell proliferation was measured by flow cytometry soon after labeling and 7 days 
after culture. A CD34-FITC antibody (clone AC136, Miltenyi, Germany) was used for 
co-staining before flow cytometry analysis to label CD34+ cells. Data was analyzed by 
using Flow Jo software (Version 7.5, Oregon, USA). 
6. AnnexinV / PI apoptosis assay 
Hematopoietic cells were stained with annexin V-FITC, according to manufacturer’s 
instructions (FITC Annexin V Apoptosis Detection Kit II, BD Pharmingen, USA). Annexin 
V binds to cells apoptotic cells, and PI is to distinguish viable cells from nonviable cells. 
Briefly, cells were washed with cold PBS, resuspended in 1x staining buffer. Then 5µl of 
annexin V-FITC and 10µl of PI reagents were added into up to 105 cells resuspended in 
100µl staining buffer, incubated for 15 minutes at room temperature, and analyzed by 
flow cytometry within 1 h. A CD34-APC antibody (Clone AC136, Miltenyi, Germany) was 
used to co-stain with these reagents before flow cytometry analysis to label CD34+ cells. 
Data were analyzed by using Flow Jo software. 
7. Analysis of surface-markers by flow cytometry 
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The phenotype of cultured hematopoietic cells was examined 7 days after seeding. 
PBS+2% FBS was used as staining buffer. Cells were washed with staining buffer twice, 
resuspended, and stained by FcR blocking Reagent (Miltenyi, Germany) for 10 min at 
4 °C followed by staining with CD34-FITC (Clone AC136, Miltenyi, Germany), 
CD38-APC (clone IB6, Miltenyi, Germany), CXCR4-PE-Vio770 (clone 12G5, Miltenyi, 
Germany), c-kit-APC-Cy7 (clone 12G5, Miltenyi, Germany),  CD41-FITC (clone HIP8, 
STEMCELL Technologies, Canada), CD71-VioBlue (clone AC102, Miltenyi, Germany), 
CD33-PE(WM53, Biolegend, USA), CD3-FITC (clone UCHT1, STEMCELL Technologies, 
Canada), CD19-APC (clone HIB19, BD Pharmingen, USA), and CD56-PE-Cy7 (clone 
B159, BD Pharmingen, USA) for 10 min at 4°C. After staining, cells were washed and 
resuspended in 400 μl staining buffer and analyzed by flow cytometry (LSR II, BD 
Biosiences). Data were analyzed using Flow Jo software. 
8. Colony forming unit (CFU) assay 
The clonogenic ability of cells cultured in different conditions was measured by CFU 
assay. After 7 days culture, cells were harvested, and washed in PBS as described 
above. Then 300 cells were added in triplicate in 1 ml of MethoCult methylcellulose 
medium supplemented with recombinant human SCF, G-CSF, GM-CSF, IL3 and 
erythropoietin (STEMCELL Technologies, Canada), which allows the growth of erythroid 
progenitors (CFU-E and BFU-E, Fig 3A), granulocyte-macrophage progenitors (CFU-GM, 
Fig 3B) and multi-potent granulocyte, erythroid, macrophage, megakaryocyte 
progenitors (CFU-GEMM, Fig 3C). Samples were plated in triplicate in 35 mm2 tissue 
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culture dishes and incubated at 37°C with 5% CO2. Colonies consisting of >30 cells were 
counted using an inverted microscope 12–14 days after plating.  
9. Transmigration assay 
The transmigration assay was used to evaluate the chemotactic responses of the cells to 
stromal cell-derived factor-1 (SDF-1) after 7 days culture. It was a two-compartment 
chamber (Corning Costar, New York, NY, USA) setting: in the upper compartment, up to 
8x104 cells in 400ul RPMI1640 with 10% FBS were seeded after harvested from each 
culture condition; while in the bottom compartment, 600 µl of RPMI1640 with 10% FBS 
and 125 ng/mL SDF-1was added. Triplicate wells were set up for each group. For each 
experimental set, the bottom compartment of two wells were filled with RPMI1640 with 
10% FBS but without SDF-1 in order to assess spontaneous migration. Cells were 
incubated at 37°C with 5% CO2 for 4 hours. Then the upper compartment was removed 
and the migrated cells in the lower compartment were harvested and counted. 
10.  Statistical analysis 
Data is presented as mean ± standard error of the mean (SEM). Comparisons between 
different culture conditions were done by using Student's t test. For all analyses, P<0.05 
was considered statistically significant. Analyses were performed using GraphPad Prism 







DWJM slowed UCB CD34+ HSPC proliferation while maintaining its primitive 
phenotype. 
We began with assessing HSPCs proliferation under our different culture conditions. 
First we counted cell numbers by trypan blue exclusion. We found that culture conditions 
that included stromal cells showed enhanced proliferation of hematopoietic cells over 
non-stromal cell conditions, while UCB CD34+ cells cultured in DWJM alone showed 
slowed proliferation (Fig 3B). Among all of the four culture conditions, stromal cell 
mono-layer showed the highest yield with a 50-fold increase compared to 26-fold in 
control. The lowest overall proliferation was observed in UCB CD34+ cells cultured in 
DWJM without stromal cell support, reaching a 7-fold increase. Although pre-seeding of 
stromal cells in DWJM supported the proliferation of UCB CD34+ cells by increasing cell 
numbers by approximately 15-fold, the proliferation was still slower than the control 
group.  
To further assess proliferation of UCB CD34+ cells, we tracked cell division by using 
CellTrace assay. Consistent with fold change in cell number data using trypan blue, bone 
marrow stromal cell mono-layer supported HSPC proliferation the most, as is shown by 
the most significant loss of violet signal. Cells undergoing 4~6 cell divisions were 
significantly increased compared to the other culture conditions. In contrast, UCD CD34+ 
cells cultured in DWJM alone did not show enhanced proliferation, as most of the cells  
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Figure 3. DWJM inhibited UCB HSPC proliferation while maintaining CD34+ 
phenotype in the majority of cells. (A) Representative histograms of CellTrace Violet 
intensity of UCB HSPC cultured on DWJM scaffolds with and without BM MSC support 
after 7 days of culture. (B) Cell number fold change of hematopoietic cells quantified 
using hematocytometer according to culture conditions (n = 3, data are expressed as 
mean ± SEM, *P < 0.05). (C) Representative CellTrace Violet/CD34 co-staining of cells 
















      

















































maintained an extremely high violet fluorescence with only a small proportion undergoing 
cell division. DWJM preseeded with stromal cells increased UCB CD34+ 
proliferation,since there were some cells undergoing 1~3 cell divisions, and the pattern 
of signal loss resembled that of cells cultured in control condition (Fig 3A).  
Since increased proliferation of HSPCs is usually at the expense of their differentiation, 
we next analyzed the ability of the cultured cells to maintain their primitive phenotype 
while undergoing proliferation by co-staining with CD34 antibody (Fig 3C). We defined 
fast-proliferating and slow-proliferating cells according to violet fluorescence intensity. In 
stromal cell mono-layer culture condition, almost all fast-proliferating cells were CD34-, 
while in the control condition, a small portion of fast proliferating cell were CD34-. In 
contrast, almost all the cells in DWJM-based 3D culture conditions were 
slow-proliferating, and they maintained the highest frequency of CD34+ expression. Thus 
DWJM alone sustained a more quiescent CD34+ cells. 
DWJM maintains UCB CD34+ HSPCs viability 
Apoptosis plays a critical role in the maintenance of HSC pool as well as lineage 
committed cells. One function of the engineered in vitro bone marrow microenvironment 
is to keep the vitality of stem cells, progenitors, and mature cells. To evalute apoptosis in 
cells cultured in each condition, we performed Annexin V / PI analysis which 
distinguishes between live (Annexin V-PI-), early apoptotic (Annexin V+PI-), late apoptotic 
(Annexin V+PI+), and necrotic (Annexin V-PI+) cells. We found that rate of apoptosis did 
not change among all the culture conditions ranging from 80%~95%, and necrosis was 
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Figure 4. DWJM maintains UCB CD34+ HSPCs viability. Apoptosis and necrosis of 
hematopoietic cells cultured according to culture conditions by co-staining of 
AnnexinV/PI and flow cytometry analysis. Results are shown as (A) density plots and (B) 

























negligible in every condition, indicating a normal cell turnover but no enhanced apoptosis 
(Fig 4 A and B). To further evaluate apoptosis of HSPCs after 7 days culture, we 
co-stained cells with CD34 antibody. The apoptosis rate of CD34+ cells was similar 
across different culture conditions (data not shown).  
DWJM enhances clonogenic potential of UCB CD34+ HSPCs 
Since proliferation is usually associated with differentiation, we performed colony forming 
assay, a functional assay to evaluate the frequency of expanded HSPCs with clonogenic 
ability, to test the capacity of different culture systems to maintain HSPC functions. 
Compared to control, HSPCs cultured in DWJM alone demonstrated approximately 
2-fold increase in all the BFU-E (p<0.0001), CFU-GM (P<0.01), and CFU-total colony 
formation (P<0.01), indicating that DWJM material maintained self-renewal and 
prevented fast differentiation of HSPCs. The pre-seeding of DWJM with bone marrow 
stromal cells also gave rise to a significant increase of CFU-GM, but not BFU-E, 
suggesting that the stromal cells embedded in DWJM might lead to myeloid 
differentiation at the expense of erythroid differentiation. Bone marrow stromal cells 
alone in monolayer did not have any influence on the clonogenic potential compared to 
control (Fig 5). 
DWJM maintains UCB CD34+ HSPCs in their primitive phenotype 
We next examined the effects of different culture conditions on maintenance of the 
primitive phenotypes of HSPCs, since one main function of stem cell niche is to keep the 
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Figure 5. DWJM increases clonogenic ability of HSPCs. (A-C) Representative 
pictures of (A) BFU-E, (B) CFU-GM, and (C) CFU-GEMM observed by using an inverted 
microscope.  (D-F) Numbers of (D) BFU-E, (E) CFU-GM, and (F) total colonies per 100 
seeded cells generated from different culture conditions. (n = 3, data are expressed as 
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pool of HSCs. To elucidate whether there will be some changes due to the HSPCs 
adhesion to DWJM or MSCs, as we saw some cells migrated into and embedded within 
DWJM (Fig 2B), we analyzed the UCB CD34+ cells in both compartments; suspension 
compartment where cells are floating in the culture well or loosely attached to DWJM; 
and adherent compartment where cells are embedded in DWJM (Fig 2B). We first 
compared the maintenance of CD34+ phenotype, which is an indicator of the HSPC 
population used for stem cell transplantation. The percentage of CD34+ cells was the 
lowest in co-culture with MSC monolayer. DWJM preseeded with stromal cells recovered 
the CD34+ phenotype compared to the stromal cell monolayer. UCB CD34+ cells 
cultured in DWJM, regardless of adherent or not, contained a higher frequency of 
CD34+ HSPCs, although the absolute increase might not be biological important (Fig 6A). 
We further analyzed the more primitive CD34+CD38- HSC population (Fig 6A). All culture 
conditions with bone marrow MSCs gave significantly lower frequency of CD34+CD38- 
cells, compared to their counterparts without stromal cells. DWJM maintained the 
CD34+CD38- population at a similar rate to control. In general, bone marrow stromal cells 
stimulated the differentiation of HSCs, while DWJM alone had minimal effects on HSC 
phenotype.  
Since we saw stem cell phenotype and functional changes, we sought to find out a 
potential mechanism giving rise to those changes. C-Kit, the ligand of stem cell factor 
(SCF), is highly expressed in cord blood CD34+ cells (data not shown). SCF also 
promotes HSC self-renewal and proliferation in vitro culture along with other cytokines 
48 
 
Figure 6. DWJM maintains CD34+CD38- phenotype while enhancing c-kit 
expression in cultured UCB HSPCs. (A) Representative contour plot and (B) 
quantification of the primitive CD34+CD38- phenotype of hematopoietic cells according 
to different culture conditions. (C) Flow cytometry scheme used to analyze c-kit 
expression in hematopoietic cells according to different culture conditions. Cells were 
stained with antibodies against CD34, CD38, and c-kit. Then the c-kit+ cell percentages 
were analyzed within CD34+ HSPCs, CD34+CD38- HSCs/MPPs, and CD34+CD38+ 
HPCs. (D) Quantification of the c-kit expression in hematopoietic cells cultured on DWJM 
scaffolds with and without stromal support after 7 days (n = 3, data are expressed as 
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(Zandstra, Conneally et al. 1997).  After culture, the CD34+c-Kit+ population were seen 
at a low frequency in all the culture conditions (1%~5%, data not shown). Although not 
statistically significant, HSPCs adherence to DWJM increased c-Kit expression, 
especially in DWJM preseeded with stromal cells (Fig 6D). We further analyzed c-Kit+ 
population within CD34+CD38- HSCs/MPPs and CD34+CD38+ oligopotent progenitors 
(Fig 6C). Within the CD34+CD38- population, the adhesion to DWJM alone enhanced 
c-Kit+ population by 1.5-fold, while DWJM pre-seeded with stromal cells enhanced c-kit+ 
cells by 2.5-fold, compared to control. However within CD34+CD38+ population, there 
was no significant change in c-Kit expression in response to adhesion (Fig 6D). 
DWJM increases UCB CD34+ HSPC CXCR4 dependent migration toward SDF-1  
One challenge for UCB transplantation is delayed engraftment partially because of 
impaired bone marrow homing. CXCR4/SDF-1 axis plays an important role in homing of 
HSC to bone marrow post-transplantation. CXCR4 is the receptor of chemokine SDF-1 
abundant in bone marrow microenvironment. We found that in freshly isolated CD34+ 
cells, the CXCR4 expression is extremely low, usually ranging from 6% to 8% (6 units 
tested). Under our tested culture conditions, DWJM suspension compartment induced 
CXCR4 expression the most, both in the total mononuclear cells and CD34+ HSPCs (Fig 
7 A and B). The adhesion to DWJM did not have any significant effect on CXCR4 
expression. In the presence of bone marrow stromal cells, CXCR4 expression was 
significantly reduced in both 2D and 3D systems (p< 0.0001 and p< 0.001). We  
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Figure 7. CXCR4/CD34+ expression is reduced in the presence of MSCs and is 
significantly increased in the non-adherence population of cells cultured with 
DWJM. (A) Representative contour plot and (B) quantification of the CXCR4 expression 
in hematopoietic cells according to different culture conditions (n = 3, data are expressed 
as mean ± SEM, **P < 0.01, ***P < 0.001, ****P < 0.0001). (C) The migration abilities 
depending on CXCR4/SDF-1 axis of the expanded cells were assessed by a transwell 




















subsequently applied transmigration assay to further assess the influence of DWJM and 
stromal cells on the homing ability of the cells from different culture conditions based on 
CXCR4/SDF-1 axis (Fig 7C). The results were consistent with CXCR4 expression 
findings: UCB CD34+ cells cultured with stromal cells demonstrated decreased migration 
to SDF-1, while UCB CD34+ cells cultured in the suspension compartment of DWJM 
showed a slight (up to 50%) but statistically ( p< 0.05) significant increased migration 
rate. However the migration rate of the cells in the adhesion compartment of the 3D 
culture systems did not show any changes compared to their non-adhesion counterparts. 
DWJM promotes megakaryocyte differentiation of UCB CD34+ HSCPs 
Since HSPCs in different culture conditions underwent various levels of differentiation, to 
obtain a detailed view of the fate of the HSPCs, we analyzed the frequency of all the 
hematopoietic lineages by staining cells with lineage specific markers. Within the 
lymphoid lineage, CD19+ B cells were extremely rare in every culture condition and were 
hardly detected by flow cytometry (all less than 0.5%). CD3+ T cell frequency was also 
very low (less than 10%), and no significant differences were seen among all culture 
conditions. CD33, a myeloid specific marker is highly expressed in hematopoietic cells 
cultured in all compartments, ranging from 80% to 98% (Fig 8B), indicating that our 
culture conditions are more prone to myeloid differentiation. We also found that there 
were no significant differences in CD71+ erythroblast differentiation as well as CD56+ 
natural killer (NK) cell differentiation (Fig 8B). However as almost all the cells are also  
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Figure 8. DWJM enhanced megakaryocyte differentiation. (A) Representative 
histograms and quantification of CD41+ frequency and (B) quantification of other lineage 
differentiation markers in the hematopoietic cells according to different culture conditions. 
The cells were analyzed for the myeloid differentiation (CD33+), megakaryocyte 
differentiation (CD41+), erythroid differentiation (CD71+), nature killer cell differentiation 























CD33+, the CD56+ NK cells might have been derived from the myeloid rather than 
lymphoid progenitors. 
Finally we measured megakaryocyte differentiation by their surface marker CD41. 
Generally bone marrow stromal cells suppressed differentiation into megakaryocytes, 
both in monolayer and DWJM systems. In contrast, we found that there was significantly 
enhanced CD41+ population within the 2 compartments of DWJM only culture system 
(Fig 8A).  
Discussion 
Current efforts focusing on factors affecting HSC fate decisions are mostly based on in 
vivo knock-out animal models (Ding, Saunders et al. 2012, Ding and Morrison 2013, 
Zhou, Ding et al. 2015). These models are able to identify the key factors in the BM niche 
but cannot recapitulate the HSC behaviors in human BM (Choi, Mahadik et al. 2015). 
Therefore an engineered bone marrow would have great clinical significance in studying 
the biology of hematopoiesis and even leukemogenesis. In addition, these models will 
help in ex vivo expansion of HSCs efforts. During the past years, attempts have been 
ongoing to engineer an in vitro culture system to mimic the bone marrow 
microenvironment (Choi, Mahadik et al. 2015). Many natural and synthetic biomaterials 
have been used to mimic the soft marrow mechanics (Lee and Kotov 2009, Lutolf, 
Doyonnas et al. 2009, Demange, Kassim et al. 2013). Since the impact of ECM on HSC 
fate decision is only poorly understood, most of the current systems are co-culture of 
HSCs with a feeder layer of niche cells to support HSC self-renewal and differentiation in 
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vitro. The bone marrow stromal cells are most commonly used niche cell population 
since they can easily be isolated from donors’ bone marrow aspirates. Studies have 
shown that in the serum-free culture conditions, these stromal feeder layers are able to 
expand HSPCs (Fraser, Szilvassy et al. 1992, Verfaillie 1992, Jing, Fonseca et al. 2010, 
Choi and Harley 2012). As the understanding of the niche is growing, the role of 
endothelial cells and bone-forming osteoblasts in maintaining HSCs are elucidated and 
co-culture with these cells populations have been shown to support long-term HSC 
expansion (Rafii, Shapiro et al. 1995, Taichman, Reilly et al. 1996, Chute, Saini et al. 
2002, Mishima, Nagai et al. 2010). Besides, they have also been shown to support the 
differentiation of HSCs to myeloid lineages including erythrocyte (Giarratana, Kobari et al. 
2005), megakaryocyte (Hatami, Andrade et al. 2015), monocyte/macrophage (Salati, 
Lisignoli et al. 2013), as well as lymphoid lineages including natural killer cells (Dezell, 
Ahn et al. 2012), T cells (Taqvi, Dixit et al. 2006), and B cells (Memon, Feingold et al. 
1992). 
In this study, we used decellularized Wharton’s jelly matrix, the ECM part of umbilical 
cord, as a scaffold material to in vitro engineer bone marrow hematopoietic niche.  We 
showed that DWJM ECM interactions maintained CD34+ cell primitive phenotype and 
self-renewal ability. Importantly, DWJM significantly enhanced the transmigration toward 
SDF-1 of the cultured UCB CD34+ cells by inducing the expression of CXCR4. The 
HSPCs cultured in DWJM also have multi-lineage differentiation potential, and were 
especially prone to the megakaryocyte differentiation. All these results indicate that 
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DWJM could serve as a candidate ECM-based model to support hematopoiesis.   
Since DWJM has never been used to culture hematopoietic cells, we first tested whether 
it was able to support the growth of cord blood CD34+ cells. We first found that DWJM 
was able to direct a small population of HSPCs migrating into it. MSCs preseeded in the 
matrix did not increase the cells embedded in DWJM significantly, suggesting that most 
of the hematopoietic cells prefer to grow in a more liquid environment. We then analyzed 
the proliferation of UCB CD34+ cells in DWJM, interestingly, cells proliferated more 
robustly in the suspension compartment with a culture medium, which further increased 
by adding BM-MSC feeder layer. Thus, adhesion to DWJM is associated with a higher 
rate of quiescence in our model. Since previous work have shown that in mouse BM, an 
overwhelming proportion of HSCs are quiescent (Acar, Kocherlakota et al. 2015), the 
next question in our study was whether the cells were able to maintain their primitive 
phenotype in DWJM-based culture system. Previous work has proved that enhanced 
HSPC expansion is at the expense of loss of primitive phenotype and stem cell functions. 
Thus, we introduced the CellTrace proliferation assay to simultaneously study cell 
division and the primitive CD34+ phenotype. Consistent with the previous findings, the 
fast-dividing cells lost the CD34+ phenotype more frequently than the slow-dividing cells, 
and cells cultured in DWJM based systems had much higher CD34+ rate compared to 
mono layer culture conditions. In contrast to previous studies (Jang, Jung et al. 2006, 
Robinson, Ng et al. 2006, Walenda, Bokermann et al. 2011), we found that the 
fast-dividing cells in BM-MSC monolayer were mostly CD34-, indicating that these 
60 
 
stromal cells strongly promote the differentiation of HSPCs. The presence of of DWJM 
rescued CD34 expression to some extent.  
As the viscosity is an important factor of BM mechanics, and ECM can increase the 
viscosity by their natural physical properties, previous studies have been done to 
investigate the relationship between viscosity and HSC maintenance. These studies 
were mostly based on specific man-made soft-gel matrix with one or several certain 
known components, making these matrix materials lack of several of the main ECM 
components in the BM (Feng, Chai et al. 2006, Sagar, Rentala et al. 2006, Leisten, 
Kramann et al. 2012). Thus, they might not recapitulate the genuine properties of BM 
ECM. In contrast, DWJM composition resembles the BM; therefore, our model is more 
appropriate to study the mechanical properties effects on hematopoietic cell proliferation. 
An interesting finding of our work is that although this biomaterial did not promote the 
expansion of HSPCs as fast as the other culture conditions, it was able to selectively 
maintain a more primitive population characterized by increased colony forming ability 
compared to the non-DWJM conditions. Since the 3D culture conditions include 2 
compartments: the non-adherent cells in suspension, and the adherent cells embedded 
within DWJM, we characterized these two compartments separately, as studies have 
shown that the niche can transmit the signals to HSPCs through adhesion molecules 
binding to their ligands including ECM proteins (Kerst, Sanders et al. 1993, Coulombel, 
Auffray et al. 1997).  
C-kit/SCF and CXCR4/SDF-1 are probably the most well-established key signaling 
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regulators of HSC maintenance (Sugiyama, Kohara et al. 2006, Ding, Saunders et al. 
2012, Ding and Morrison 2013, Greenbaum, Hsu et al. 2013), thus we sought to find out 
whether there were any changes of c-kit or CXCR4 expression in the cells cultured in 
different conditions. We found that adhesion of CD34+ cells to DWJM resulted in higher 
c-kit expression; we further analyzed the c-kit expression within CD34+ CD38- population.  
The fact that adhesion to DWJM prevented the loss of c-kit within CD34+CD38- 
population is one reason of the increased self-renewal.  
As ECM in BM serves as a reservoir of many cytokines and growth factors, along with 
the fact that our previous mass-spec study found that some soluble signaling molecules 
such as TGF- β and protein kinase are present in DWJM even after many processing 
procedures including strong washing, it is likely that DWJM binds to SCF and accordingly 
prevents the diffusive loss or even the c-kit/SCF internalization by cells upon 
ligand-receptor interaction (Jahn, Seipel et al. 2002). This might improve the 
downstream signaling initiated by this receptor protein kinase. 
CXCR4/SDF-1 axis is considered the main pathway affecting the homing efficiency of 
HSCs after transplantation (Lapidot, Dar et al. 2005). Since the CXCR4 expression is 
extremely rare in freshly isolated CD34+ cells, it is perhaps one reason causing the 
delayed engraftment in UCB transplantation due to low homing efficiency. Interestingly, 
the two compartments of our DWJM showed different abilities in inducing CXCR4 
expression: the CD34+ cells in non-adherent compartment had significantly higher 
CXCR4 frequency, while no increase in CXCR4 expression in the adherent population 
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was found. Our transmigration study further confirmed that transmigration potential was 
not induced by adhesion to DWJM.  
As BM is the main site for adult hematopoiesis, it is important that the engineered BM 
niche is capable of support the multi-lineage differentiation of HSCs. While cord blood 
C34+ cells were able to sustain the differentiation of almost all the cell types in both 
myeloid and lymphoid lineages, DWJM significantly promoted megakaryocyte 
differentiation by at least two fold. Since some recent works indicate that these 
megakaryocytes play an important role in HSC quiescence by secreting TGF-β1 , 
CXCL4 and TPO (Bruns, Lucas et al. 2014, Nakamura-Ishizu, Takubo et al. 2014, Zhao, 
Perry et al. 2014), it might also be one reason that these cells derived from CD34+ cells 
prevented the differentiation-prone proliferation of HSCs. This observation is important 
since delayed platelet recovery is prevalent among patient undergoing cord blood stem 
cell transplantation (Gluckman 2000) . Using mononuclear cells cultured in the presence 
of DWJM will potentially help shorten the time for platelet recovery, overcoming one of 
the main drawbacks of cord blood stem cell transplantation. 
In conclusion, our novel DWJM based culture system provides two main components of 
the bone marrow niche: BM stromal cells and ECM. The in vitro DWJM-based system of 
the bone marrow niche allows us to study the influence of different niche components on 
normal and malignant hematopoiesis including proliferation, differentiation, and 
























Relapse of Acute Myeloid Leukemia (AML) results from the survival of 
chemotherapy-resistant and quiescent leukemia stem cells (LSC). These LSCs reside in 
the bone marrow microenvironment comprised of other cells and extracellular matrix 
(ECM) that facilitates LSC quiescence through expression of cell adhesion molecules. 
We used decellularized Wharton’s jelly matrix (DWJM), the gelatinous material in the 
umbilical cord which contains many components of bone marrow extracellular matrix 
including collagen, fibronectin, lumican, and hyaluronic acid (HA), as a scaffolding 
material to culture leukemia cells. Leukemia cells cultured in DWJM demonstrated 
decreased proliferation without undergoing significant differentiation. In addition, 
leukemia cells showed changes in morphology with a spindle-shaped appearance after 
culture in DWJM. Also, there was an increase in ALDH+ cell population. When treated 
with a high dose of doxorubicin, leukemia cells in DWJM demonstrated less apoptosis 
compared to cells in suspension. Serial colony forming unit (CFU) assay indicated 
leukemia cells in DWJM resulted in increased colony-forming ability both after primary 
and secondary plating. This could be explained by an induction of a cell adhesion 
molecule N-cadherin expression. Our data suggest that DWJM could serve as an 






Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy 
characterized by an aberrant clonal expansion of undifferentiated myeloid blasts. Studies 
have shown that leukemic stem cells (LSCs) account for relapse after chemotherapeutic 
treatment (Wang and Dick 2005). Like normal stem cells, LSCs maintain their 
self-renewal ability while generating clonogenic leukemic progenitors which finally lead 
to the production of leukemic cells (Hope, Jin et al. 2004). Because anti-proliferative 
chemotherapeutic agents commonly target the rapidly cycling leukemic cells which are 
mainly in the circulation, it is important to develop therapeutic strategies which eliminate 
the LSCs in the bone marrow where they share the “hematopoietic niche” along with 
normal hematopoietic stem cells (HSCs) (Lo Celso, Fleming et al. 2009). LSCs hijack the 
hematopoietic stem cell niche to their advantage. The LSC niche, similar to the 
hematopoietic niche, is a three-dimensional (3D) microenvironment composed of bone 
marrow stromal cells and extracellular matrix (ECM) components like collagen, 
fibronectin and tenascin (Lo Celso, Fleming et al. 2009). They create compartments that 
not only provide the structural support to the cells in the bone marrow, but also provide 
chemokines and cytokines which are important in regulating HSC and LSC self-renewal, 
trafficking, proliferation and differentiation (Lane, Scadden et al. 2009).  
Currently, most leukemia in vitro studies are based on conventional two-dimensional (2D) 
cultures on tissue culture polystyrene (TCP) dishes/ flasks, or animal models. These 
models are useful in elucidating some of the molecular mechanisms of leukemia 
initiation and progression. However, the 2D culture system lacks the 
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leukemia-microenvironment interaction in the 3D bone marrow microenvironment, and 
the LSC frequently differentiate and lose their “stem-ness”, while the expensive in vivo 
animal models cannot fully mimic the human bone marrow microenvironment which 
regulates leukemia proliferation, differentiation, and chemoresistance. Thus, the 
development of an in vitro 3D model that possesses the bone marrow mechanical and 
molecular properties could be useful in overcoming these challenges in in vitro leukemia 
culture systems. Previously our lab established a 3D stromal based model for testing 
AML chemoresistance. Briefly, in co-culture with primary bone marrow mesenchymal 
stromal cells (MSCs) seeded in PGA/PLLA scaffold, AML cells showed increased 
chemoresistance. Our next goal is to test whether another main component of bone 
marrow stem cell niche, the ECM, could also play a role in chemoresistance, or even be 
able to enrich a subpopulation with stem cell properties (Aljitawi, Li et al. 2014). For the 
last few years we have been interested in studying decellularized Wharton’s jelly matrix 
(DWJM) for regenerative medicine applications (Aljitawi, Xiao et al. 2013). As previously 
described, Wharton’s jelly is the gelatinous connective tissue of the umbilical cord that 
mainly supports blood vessels in umbilical cord. Its components such as collagen, 
fibronectin, hyaluronic acid (HA), and sulphated proteoglycan (Sobolewski, Bankowski et 
al. 1997, Franc, Rousseau et al. 1998) also exist in the bone marrow hematopoietic 
niche (Lo Celso, Fleming et al. 2009). In addition, DWJM could also serve as a reservoir 
for some soluble growth factors such as Insulin-like growth factor 1 (IGF-1), Fibroblast 
Growth Factor (FGF), Transforming growth factor beta 1 (TGF-β1), Epidermal growth 
factor (EGF), and Platelet-derived growth factor (PDGF) (Sobolewski, Malkowski et al. 
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2005). Thus, we hypothesized that our DWJM can be used to establish an in vitro model 
to study LSCs. We evaluated decellularized Wharton’s jelly matrix (DWJM) as a 3D 
extracellular matrix (ECM) model to study leukemia. Briefly, we investigated the growth 
pattern including proliferation, viability, morphology and myeloid differentiation of 3 
human leukemia cell lines HL60 (acute promyelocytic leukemia), Kasumi-1 (acute 
myeloblastic leukemia), and MV411 (biphenotypic B myelomonocytic leukemia) in the 
model, to reflect the different subtypes of AML. We also compared the drug resistance 
and stem cell characteristics of leukemia cells in the model with leukemia cells in 
suspension. We found that AML cells grown in our ECM model using DWJM had 
preserved LSC-like characteristics, suggesting that DWJM may prove useful for the 
further characterization and targeting of LSC.  
Materials and Methods 
1. Cell culture 
Human AML cell lines HL60, Kasumi I and MV 411 (ATCC, Manassas, VA) were 
maintained in T 75 tissue culture flasks with Advanced Roswell Park Memorial Institute 
(RPMI) 1640 Medium (Gibco) supplemented with 5% fetal bovine serum (Sigma-Aldrich) 
and 1% penicillin/streptomycin (pen/strep) (Life Technologies). Cells were maintained at 
37°C in a fully humidified 5% CO2 incubator for the experiment.  
2. DWJM scaffolds preparation 
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Figure 9. Characterization of DWJM. (A) DWJM scaffolds of larger chunks (left) and 
small wafers (right). The small wafers were used as scaffolds for leukemia cells. (B) 
Comparison of main components in DWJM and bone marrow ECM.  
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The preparation of DWJM was described above in Chapter 2. After decellularization, the 
DWJM were cut into small scaffolds (Figure 9A). This ECM material is composed of  
many proteins and glycosaminoglycans which are also found in bone marrow 
microenvironment (Figure 9B). 
3. Seeding DWJM wafers with AML cell lines 
Before seeding, cryopreserved DWJM wafers were thawed, washed in phosphate 
buffered saline (PBS) three times, and pre-incubated with Advanced RPMI overnight. 
AML cells (2*105 cells/well) were seeded into DWJM wafers in 24-well non-tissue culture 
treated plates with 60% area of each well covered by DWJM. Culture plates were then 
placed in an incubator at 37°C with 5% CO2 and maintained in Advanced RPMI with 5% 
FBS for 7 days and half the medium was changed every other day. AML cells in 
suspension (2*105 cells/well) cultured under the same conditions were used as control. 
In AlamarBlue assay, CellTrace proliferation and Ki67 immunohistology sample 
preparation, cells were maintained in RPMI 1640 (Sigma-Aldrich) with 10% FBS for 
HL60 and MV411, and 20% FBS for Kasumi I. 
4. AlamarBlue assay 
To assess the proliferation of AML cells, DWJM wafers with cells were transferred to new 
24 well plates and washed with PBS three times 4 hours prior to proliferation 
assessment. Ten percent alamarBlue (Biocentric) was added into each well. After 4 
hours, 100 µl supernatant of each well was aspirated to a new well of a 96 well plate and 
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fluorescence was measured by micro-plate reader with excitation wavelength at 530nm 
and emission wavelength at 590 nm. 
5. CellTrace proliferation assay 
To monitor the cell division of leukemia cells in both suspension and DWJM, cells were 
labeled with CellTrace Violet (Life Technology) before seeding. Briefly, cells were 
washed and resuspended with PBS at the concentration of 106cells/ml, and CellTrace 
Violet stock solution was added in a final concentration of 1µl/ml. After incubation at 
room temperature for 20 minutes 5ml of PBS with 10% FBS were added and incubated 
for 5 minutes followed by centrifugation to obtain pellets. Cells were resuspended in 
culture medium and cultured in either suspension or DWJM. Cell division was 
determined by flow cytometry soon after seeding and after 7 days of culture. To isolate 
cells from DWJM, we washed wafers in PBS, and then used collagenase II to digest 
DWJM at 37°C. 
6. Cell viability 
Cell survival in DWJM was measured by Vi-CELL Series Cell Viability Analyzer 
(Beckman Coulter) which is based on Trypan Blue dye exclusion. Cells in each DWJM 
wafer were released by treating with 1ml 0.002g/ml collagenase II (Worthington) for 
about 2 hours in 37°C. The released cells were assessed for viability according to 
manufacturer’s recommendations.  
7. Histology and Immunohistochemistry 
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For morphological analysis, wafers were washed with PBS three times, fixed in 4% PFA, 
embedded in paraffin, sectioned and stained with hematoxylin and eosin, and visualized 
under the microscope using Olympus BX40 microscope and pictures were obtained 
using DP72 digital camera.  
 
For immunohistochemistry, formalin-fixed, paraffin-embedded sections (4µm) were 
subjected to immunohistochemical staining of Ki67 and N-Cadherin. Briefly, after 
deparaffinization and rehydration, tissue sections were treated using citrate buffer (pH 
6.0) for 5 min in a pressure cooker for antigen retrieval. Hydrogen peroxide (3%) was 
then applied to the sections to quench endogenous peroxidase activity. Sections were 
then incubated with primary antibodies against Ki67 (clone MIB-1; 1:200 dilution; Dako, 
Carpinteria, CA, USA) and N-Cadherin (1:100 dilution; Immuno-Biological Laboratories 
Co., Minneapolis, MN, USA) for 30 min at room temperature respectively. After extensive 
rinsing, Ki67 sections were incubated with anti-mouse HRP-labeled polymer (EnVision 
TM + System, Dako, Carpinteria, CA, USA), while N-Cadherin sections are incubated with 
MACH 2TM Rabbit HRP-Polymer (Biocare Medical, Concord, CA, USA). Finally, the 
staining was visualized by DAB (Dako, Carpinteria, CA, USA), and nuclei were 
counterstained with hematoxylin. All immunohistochemical staining was performed using 
the IntelliPATH FLX TM Automated Stainer (Biocare Medical, Concord, CA, USA) at room 
temperature. Slides were assessed by Automated Cellular Imaging System (ACIS).  
8. Treatment with chemotherapy 
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After 7 days, both cells cultured in suspension and cells in DWJM were treated with 
50µM of doxorubicin hydrochloride (Sigma-Aldrich) for 48 hours. For cells in suspension, 
culture medium was removed, and chemotherapeutic agents were added in fresh 
medium. For cells in DWJM, scaffolds were transferred into new 24-well plates, washed 
with PBS three times followed by adding chemotherapeutic agent in culture medium. 
9. Apoptosis assay 
Apoptosis in leukemia cells was measured by flow cytometry using Annexin V-Alexa 568 
(Invitrogen, USA) and DAPI (Invitrogen, USA) staining. Prior to flow cytometry analysis, 
cells in DWJM wafers were released as described previously and 105released cells as 
well as cells in suspension were stained with DAPI and Annexin V according to 
manufacturer’s recommendations, and data were acquired within 1 hour by using LSR II 
(BD Biosciences), and analyzed by FlowJo software. 
10. Aldefluor assay 
Aldehyde dehydrogenase (ALDH) activity was examined by using Aldefluor reagent 
(Stem Cell Technologies) according to the manufacturer’s protocol followed by flow 
cytometry. Cells negative for propidium iodide (PI) staining were considered positive for 
ALDH based on a negative control using ALDH inhibitor diethylaminobenzaldehyde 
(DEAB). Data were analyzed within 1 hour by using LSR II (BD Biosciences). 
11. Analysis of differentiation marker 
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Expression of CD11b was measured by flow cytometry. 105 cells cultured in suspension 
or in DWJM were harvested and incubated with FITC-conjugated anti-human CD11b 
(Abcam) for 10min at room temperature. After staining cells were washed and 
resuspended in 400µl PBS and analyzed by flow cytometry by using LSR II (BD 
Biosciences).  
12. Colony Forming Unit (CFU) Assay 
Cells were plated on 35 mm dishes (500 cells/dish for Kasumi I, and 300 cells/dish for 
HL60 and MV411) in triplicate in MethoCult® H4434 Classic methylcellulose (Stemcell 
Technologies, Vancouver, Canada). Cells were washed and resuspended in RPMI 1640 
medium. After determining cell number and viability by trypan blue, cell density were 
adjusted at a concentration of 10 cells/µl, and cells were added into methylcellulose 
followed by adding 1ml cell- methylcellulose mix into each dish. After 12-14 days of 
incubation at 37ºC and 5% CO2, colonies consisting of >30 cells were counted, then 
harvested and replated in methylcellulose. After another 12-14 days, colonies were 
counted. 
13. Data analysis 
All data analyses are done with Graphpad Prism 6 (GraphPad Software, Inc.) and 
presented as means ± standard deviation (SEM) and significance are determined using 
Student’s t-tests. Statistical significance was determined by a statistical threshold of p 




DWJM decreases leukemia cell proliferation while maintaining cell viability 
Leukemia cell proliferation in DWJM was characterized by AlamarBlue assay on days 2, 
4, and 6 after seeding. All the three cell lines HL 60, Kasumi I and MV411, showed 
decreased proliferation while growing in DWJM during the first week after seeding 
(Figure 10A). Since it is possible that the decreased proliferation was due to the lower 
cell viability in DWJM, accordingly we also measured cell viability at the same three time 
points. We found that all the three cell lines maintained nearly unchanged viability at the 
three time points (Figure 10B). To further compare cell division in DWJM to suspension, 
we pre-labeled seeded leukemia cells with CellTrace Violet reagent prior to culture 
(Figure 10C). Consistent with AlamarBlue assay, after 7 days, cells in suspension lost 
more fluorescence compared to cells in DWJM, indicating that cells in DWJM turned to 
be more quiescent. At the same time we used Annexin V/PI staining to assess cell 
apoptosis. There was no significant difference between cells in suspension and DWJM 
(Figure 10D). 
Leukemia cells in DWJM switch to spindle-shaped morphology 
We noticed that HL 60 and Kasumi I cells cultured in DWJM tend to change their 
morphology, switching from round, which is the morphology of AML cells in suspension, 
to spindle shape 7 days after seeding (Figure 11A and B). In general, there were more 
spindle-shaped cells than round cells per high power field (HPF) (Figure 11C). The round 
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Figure 10.  DWJM decreases leukemia cell proliferation while maintaining cell 
viability. (A) HL60, Kasumi 1 and MV411 cells were seeded and allowed to adhere and 
penetrate DWJM for 2 days. Then DWJM with cells were taken to a new plate, and 
AlamarBlue assay were used to assess cell proliferation on day 2, 4, and 6. Data is 
normalized to day 2 fluorescence reading. (B) Collagenase II was used to release cells 
embedded in DWJM, and cell viability was assessed by Vi-CELL based on trypan blue 
exclusion on day 2, 4, and 6. All values represent means ± SEM. (C) Violet intensity of 
HL60 and MV411 in DWJM and suspension before and 7 days after seeding. D: 
Apoptosis and necrosis of HL60 and MV411 cultured in suspension or DWJM by 
co-staining of AnnexinV/PI and flow cytometry analysis. Results are shown as density 
plots (upper) and quantification (bottom). Data represent means ±SEM. Experiment 





















cells are mostly seen in the open spaces within the matrix, while the spindle shaped cells 
are mostly embedded inside the matrix.   
DWJM keeps leukemia cells undifferentiated while increasing the stem/progenitor 
cell marker ALDH+ population 
As CD11b is a common myeloid marker (Dziennis, Van Etten et al. 1995), we evaluated 
CD11b expression to estimate differentiation levels of the three AML cell lines. Neither 
the cells in suspension nor cells in DWJM expressed CD11b, indicating that the matrix 
maintains leukemia cells in an undifferentiated stage (Figure 12A). Next we examined 
the expression of stem cell marker ALDH. High ALDH expression has been reported in 
several lineages of cancer precursor cells including hematopoietic, mammary, 
endothelial, mesenchymal, and neural, indicating that the ALDH+ population may be 
more tumorigenic. We found that in both Kasumi I (~7 fold, p<0.05) and MV411 (~2 fold, 
p<0.05), cells cultured in DWJM significantly increase ALDH activity, compared with cells 
in suspension (Fifure 12B), while HL60 did not show any difference (data not shown). 
DWJM increases leukemia cell clonogenic ability  
Since ALDH enriches both cancer stem and progenitor cells, to examine the self-renewal 
of leukemia cells cultured in DWJM, we used serial CFU assay, as primary CFU assays 
demonstrate progenitor potential of leukemia cells, and secondary replating correlates 
with self-renewal ability. In general, in all the three cell lines, colony number from both 
primary and secondary plating increased significantly (Figure 13). In two cases, the 
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Figure 11. Leukemia cells in DWJM switch to spindle-shaped morphology. (A) A 
representative of H&E staining of HL60 (left), Kasumi 1 (middle) and MV411 (right) cells 
cultured in DWJM for one week (40x). (B) Kasumi 1 cells switch from round to 
spindle-shaped. Left: round; middle: round-spindle; right: Spindle (100x). C: Number of 





























Figure 12. DWJM keeps leukemia cells undifferentiated while increasing the 
stem/progenitor cell marker ALDH+ population. (A) CD11b expression in HL60 and 
Kasumi 1 cultured in suspension and DWJM. (B) Representative density plots (upper) 
and quantification (bottom) of Aldefluor assay of MV411 and Kasumi 1 after 7 days 


























increase approached statistically significant in Kasumi 1 after primary plating (figure 13C, 
p=0.08) and MV411 after secondary plating (figure 13B, p=0.051). In all leukemia cells 
cultured in DWJM they gained long-term self-renewal ability as the colony-forming ability 
was maintained even 28 days after their release from DWJM.   
DWJM enriches leukemia cells with increased drug resistance 
As leukemia stem cells are more chemoresistant, and are responsible for disease 
relapse after chemotherapy, we next investigated doxorubicin’s effects on leukemia cells 
in both suspension and DWJM. We used a very high dose, 50µM, which killed more than 
95% of cells in suspension after 48 hour treatment (Figure 14 A and B), to treat leukemia 
cells in both culture conditions. After 48h treatment, we used Annexin V/DAPI to assess 
cell apoptosis/necrosis. As expected, doxorubicin induced cell death mainly through 
apoptosis. We observed that the survival rate of cells cultured in DWJM significantly 
increased in all three cell lines HL60 (~2.5 fold, p<0.5), Kasumi I (~8 fold, p<0.05), and 
MV411 (~5 fold, p<0.1) (Figure 14 A and B), suggesting that culture in DWJM could have 
protected leukemia cells from the cytotoxicity of anti-cancer drugs. We further analyzed 
doxorubicin uptake by measuring its fluorescent intensity and found that the 
accumulation of doxorubicin decreased in leukemia cells cultured in DWJM (Figure 14 C). 
Since N-cadherin was reported as a stem cell marker and lead to CML stem cell drug 
resistance by activation of Wnt signaling, we further analyzed N-cadherin expression and 
found that cells in DWJM increased N-cadherin expression compared to cells in 
suspension (Figure 14D). 
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Figure 13. DWJM increases leukemia cell clonogenic ability. Clonogenic ability of 
HL60 (A), MV411 (B), and Kasumi 1 (C) after cultured in DWJM or suspension for 7 days. 







































In this study, we used DWJM as an ECM model to develop a novel 3D in vitro leukemia 
culture system representing different AML cell lines. Our first finding is that DWJM 
supports leukemia cell migration and maintains cell viability. The comparatively lower cell 
division rate, along with the maintenance of cell viability, suggests that this matrix keeps 
cells in a more quiescent state. Since the quiescent subpopulation of AML cells counted 
for the disease relapse after chemotherapy, our findings suggest that DWJM might be 
able to enrich leukemia cells with stem cell characteristics. We next measured the 
expression of CD11b, a myeloid differentiation marker to see whether DWJM could 
maintain leukemia cells in an undifferentiated state. We found the expression of CD11b 
was negligible both in suspension and DWJM, indicating that such ECM material does 
not cause differentiation of leukemia cells. We also examined intracellular ALDH activity 
since it has been reported to enrich normal stem cells including hematopoietic stem cells 
(Kastan, Schlaffer et al. 1990, Storms, Trujillo et al. 1999), cancer stem cells in breast 
cancer cell lines (Croker, Goodale et al. 2009), as well as leukemia stem cells in patient 
bone marrow samples (Gerber, Smith et al. 2012). We found that after culturing leukemia 
cells in DWJM, there was an increase in ALDH+ population in both Kasumi 1 and MV411. 
These findings suggest that our system favored LSC-like phenotype and behavior over 




Figure 14. DWJM enriches leukemia cells with increased drug resistance. (A) 
Representative density plots and (B) quantification of apoptosis and necrosis in HL-60, 
Kasumi I and MV411 in either DWJM or suspension were measured after treated with 
50µM doxorubicin for 48 hours. Data represent means ± SEM. Experiment done in 
triplicate. *P<0.05; **P<0.01. (C) Doxorubicin uptake in HL60 (left) and MV411 (right) 
cells after treatment. (D) N-cadherin expression in HL60 (left) and MV411 (right) after 7 
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Like normal HSCs, leukemia stem cells also possess strong self-renewal ability and it is 
required for the long-term disease maintenance. To assess the self-renewal ability of 
leukemia cells in DWJM, we used serial CFU assay by counting colony numbers formed 
after both primary plating and secondary replating, since it has been reported as an ideal 
in vitro assay complementary to serial transplantation (Lin, Wang et al. 2010). Our result 
showed that the clonogenic ability of leukemia cells was increased by DWJM in both 
primary and secondary plating, meaning the self-renewal was long-lasting.  
Chemoresistance is one of the major characteristics of cancer stem cells, and is also a 
main obstacle leading to the failure of chemotherapy (Holohan, Van Schaeybroeck et al. 
2013). It is well-known that some components in the microenvironment play an important 
role in inducing cancer cell drug resistance (Konopleva and Jordan 2011). Previous 
studies also found that different types of cancer cells increased drug resistance when 
cultured in 3D collagen gels (Dangi-Garimella, Sahai et al. 2013, Leung, Moraes et al. 
2015), and lymphoma cell adhesion to fibronectin acquired resistance to mitoxantrone 
(Hazlehurst, Argilagos et al. 2006). Since these components are all present in DWJM, 
we assessed whether DWJM could help shelter leukemia cell from chemotherapy. (Asou, 
Tashiro et al. 1991, Gu, Cimino et al. 1992, Jackson, Schenker et al. 1994, Tsuruo, Naito 
et al. 2003, Lee, Kuo et al. 2005, Palle, Frost et al. 2005, Cordo Russo, Garcia et al. 
2008, Brown, Reinke et al. 2011, Louderbough and Schroeder 2011, Lompardia, 
Papademetrio et al. 2013). The fact that more cells cultured in DWJM, compared to 
suspension, survived after high dose of doxorubicin treatment confirmed our hypothesis, 
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and this was at least partly because of the decreased intake of this chemotherapeutic 
reagent. 
We also saw a morphology change while cells were growing in DWJM—there were more 
spindle-shaped cells rather than their natural, round shape in cell suspension and 
circulation in human body. Similarly, Mochmann et al. found that the spindle-shaped 
leukemia cells were more chemoresistent (Mochmann, Neumann et al. 2013). This is 
consistent with our findings that this model enriched for spindle cells and cells cultured in 
DWJM were more chemotherapy resistant. In addition, we observed that leukemia cells, 
in DWJM strongly express N-cadherin, a chemoresistance mediator, while we could 
hardly see N-cadherin in cells cultured in suspension.   
In conclusion, our ECM model using DWJM supports leukemia cell growth and enriches 
a stem-like population. DWJM should be further examined as a platform for leukemia 



























Hematopoietic stem cells (HSCs) are widely used in cell and gene therapies to treat 
hematologic and non-hematologic diseases mainly by transplanting HSCs to the affected 
host. However, the limited number of such cells, especially in the case of umbilical cord 
blood transplants, is a barrier for using HSCs in clinical applications. Therefore, ex vivo 
expansion of HSCs, especially umbilical cord blood HSCs, overcomes this barrier and 
provides an adequate number of HSCs to treat patients.  
As bone marrow (BM) is the main organ for adult hematopoiesis as well as the location 
of most HSCs, engineering a BM hematopoiesis niche in vitro provides a simplified but 
useful tool to study the biology of HSCs and provides a model to expand HSCs for 
potential clinical use. The main purpose of my dissertation was to use a novel natural 
extracellular matrix (ECM) biomaterial, decellularized Wharton’s jelly matrix (DWJM), to 
engineer a BM niche and characterize umbilical cord blood HSCs (CD34+ cells) behavior 
in the DWJM-based culture system. Further, I examined the effects of other BM niche 
components; BM stromal cells (MSCs) and soluble cytokines and growth factors, on cell 
proliferation, viability, clonogenic ability, stem cell phenotype, homing potential, and 
multi-lineage differentiation. Since leukemia stem cells (LSCs) hijack the BM niche and 
its’ components, we also cultured three leukemia cell lines representing different 
leukemia subtypes, in DWJM, to further elucidate the influence of DWJM on the 
maintenance of leukemia cell stem-ness. 
In our HSC study, we chose to use a commercially available cytokine cocktail cc110 
consisting of Flt3L, SCF, and TPO in all culture conditions as HSCs did not survive in 
serum-free culture medium(data not shown). Firstly, we have proved that DWJM is a 
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biomaterial suitable for engineering BM hematopoietic niche since HSCs could be 
maintained viable during 7-day culture. Similarly the leukemia cells did not show a 
change in viability when cultured in DWJM. We next analyzed stem/progenitor 
self-renewal by colony-forming unit assay, HSC phenotype by flow cytometry, and 
homing potential by investigating CXCR4/SDF-1 axis by both flow cytometry and 
transwell assay. Our results indicate that umbilical cord blood CD34+ cells cultured in the 
presence of DWJM demonstrate stem-like behavior evident by their quiescence while 
maintaining their clonogenic ability, increased C-kit+ population within the CD34+CD38-  
HSPCs, and stronger homing potential related to increased CXCR4 expression and 
improved migration toward SDF-1. The role of DWJM in supporting stem-ness was 
further demonstrated by the leukemia cell behavior when leukemia cells were cultured in 
this ECM material. Like in the case of HSCs, DWJM enriched a sub-population of 
leukemia cells with stem cell-like characteristics including an increased quiescent 
population, an enhanced ALDH expression in the cultured cells, enhanced clonogenic 
ability, and increased drug resistance. Drug-resistance in our model was associated 
decreased intracellular drug availability after treatment. Also, cultured cells preferentially 
exhibited spindle-shaped phenotype. The induction of N-cadherin in the cultured cells is 
a potential mechanism for stem cell phenotype. The downstream signaling pathways of 
N-cadherin including PI3K signaling and Wnt pathway is worth study in the future. Since 
it has been reported that the activation of β-catenin is important in the survival of LSCs in 
chronic myeloid leukemia (CML), next we sought to find out whether it also plays a role in 
protecting LSCs in AML. By testing this, we will try to block N-cadherin in our 3D 
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leukemia model, and assess whether they are still drug-resistant. We can also try to 
over-express or knock down N-cad in the leukemia cell lines, and assess the effects of 
N-cadherin in the cells in cell proliferation, self-renewal, and morphology change. To 
study the interaction between N-cadherin and Wnt signaling, we will also analyze the 
expression of N-cadherin, β-catenin, and P-GSK3β, as well as the interaction of 
N-cadherin and β-catenin. Last but not the least, we will try to use gene expression 
profile to compare the change of genes in stem cell self-renewal, quiescence, cytokine 
signaling, adhesion, metabolism, and cell cycle in cells cultured A) in DWJM vs. 
suspension, and cells B) enriched in n-cadherin and (C) β-catenin. 
We also found that DWJM enhances CD41+ megakaryocytic differentiation of umbilical 
cord blood HSCs. Our model not only provides a model to study megakaryocyte 
differentiation, but also helps to elucidate the role of megakaryocyte in HSC 
maintenance. This finding has a strong clinical relevance; by using the DWJM-based 
model to expand CD34+ cells for transplantation, we enhance hematopoietic 
reconstitution ability by alleviating the risk of delayed platelet recovery. 
We also evaluated BM-MSCs role in maintaining HSC stemmness in our in vitro culture 
system. Our results indicate that BM-MSCs induce HSC differentiation and lead to 
impairing SFD-1 driven transmigration. Since the stromal cells are heterogeneous, 
further studies are need to understand the specific role of each sub-population within 
these cells on HSC biology and function. 
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In conclusion, we propose that DWJM-based model maintains HSCs while the presence 
of stromal cells lead to their differentiation. Thus, DWJM as an ECM biomaterial-based 
model can be used as a BM engineered in vitro niche that can be used to expand cord 
blood HSCs for clinical transplantation and could be utilized to study LSCs as well as 
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